Venkatesan Jay 4

What Happened Venkatesan Jay, a director of Serina Therapeutics, received 7,553 shares of common stock on March 31, 2026. The shares were recorded at $1.94 each, for a total value of $14,653. This was an award/other acquisition (code A) — not an open-market purchase or sale.

Key Details

• Transaction date and price: 2026-03-31 at $1.94 per share (total $14,653).
• Shares acquired: 7,553 common shares.
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnote: The shares were issued to satisfy accrued dividends on the reporting individual’s A Convertible Preferred Stock (issued April 8, 2025).
• Filing timeliness: Form 4 was filed on 2026-04-21 (filed late relative to the transaction date).

Context This was a dividend-in-kind / share issuance to cover accrued dividends on convertible preferred stock, rather than a market purchase or sale. Such issuances are typically administrative and do not by themselves indicate insider buying or selling intent. The late filing may affect timeliness disclosure but does not change the nature of the transaction.